Phosphodiesterase 5 inhibitors in vascular systemic disorders

Joint Bone Spine

Volumn 79, Issue 4, 2012, Pages 338-340

  Allanore, Yannick ^a  

^a INSTITUT COCHIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; ENDOTHELIN RECEPTOR ANTAGONIST; GUANOSINE PHOSPHATE; GUANOSINE TRIPHOSPHATE; ITRACONAZOLE; KETOCONAZOLE; NITRATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; RITONAVIR; SILDENAFIL; TADALAFIL; VARDENAFIL; VASODILATOR AGENT;

ADD ON THERAPY; CARDIOPULMONARY FUNCTION; CELL PROLIFERATION; CONNECTIVE TISSUE DISEASE; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERABILITY; DYSPEPSIA; EDITORIAL; ENDOTHELIUM CELL; ERECTILE DYSFUNCTION; FINGER ULCER; FLUSHING; GAS EXCHANGE; HEADACHE; HEART INDEX; HUMAN; LUNG ARTERY PRESSURE; LUNG FIBROSIS; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MYALGIA; NONHUMAN; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAYNAUD PHENOMENON; SIDE EFFECT; SYSTEMIC CIRCULATION; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; VASCULAR DISEASE; VASODILATATION; VISUAL ANALOG SCALE;

ANIMALS; CARBOLINES; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; PENILE ERECTION; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; SULFONES; VASCULAR DISEASES; VASODILATOR AGENTS;

EID: 84863218444     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.12.009     Document Type: Editorial

References (20)

1. Wharton J., Strange J.W., Møller G.M., et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005, 172:105-113.
2. Kass D.A., Takimoto E., Nagayama T., et al. Phosphodiesterase regulation of nitric oxide signaling. Cardiovasc Res 2007, 75:303-314.
3. Palit V., Eardley I. An update on new oral PDE5 inhibitors for the treatment of erectile dysfunction. Nat Rev Urol 2010, 7:603-609.
4. Montani D., Chaumais M.C., Savale L., et al. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Adv Ther 2009, 26:813-825.
5. Ghofrani H.A., Wiedemann R., Rose F., et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002, 360:895-900.
6. Sastry B.K., Narasimhan C., Reddy N.K., et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004, 43:1149-1153.
7. Ghofrani H.A., Voswinckel R., Reichenberger F., et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004, 44:1488-1496.
8. Galiè N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005, 353:2148-2157.
9. Badesch D.B., Hill N.S., Burgess G., et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 2007, 34:2417-2422.
10. Galiè N., Brundage B.H., Ghofrani H.A., et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009, 119:2894-2903.
11. Jing Z.C., Yu Z.X., Shen J.Y., et al. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med 2011, 183:1723-1729.
12. Hinchcliff M., Fischer A., Schiopu E., et al. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population. J Rheumatol 2011, 38:2172-2179.
13. Koumakis E., Wipff J., Kahan A., et al. Pulmonary arterial hypertension occurrence after liver transplant in systemic sclerosis: a report of 2 cases sustainably treated by sildenafil. Clin Exp Rheumatol 2010, 28:S53-S54.
14. Herrick A.L. Contemporary management of Raynaud's phenomenon and digital ischaemic complications. Curr Opin Rheumatol 2011, 23:555-561.
15. Botzoris V., Drosos A.A. Management of Raynaud's phenomenon and digital ulcers in systemic sclerosis. Joint Bone Spine 2011, 78:334-341.
16. Fries R., Shariat K., von Wilmowsky H., et al. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 2005, 112:2980-2985.
17. Brueckner C.S., Becker M.O., Kroencke T., et al. Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann Rheum Dis 2010, 69:1475-1478.
18. Herrick A.L., van den Hoogen F., Gabrielli A., et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum 2011, 63:775-782.
19. Shenoy P.D., Kumar S., Jha L.K., et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology (Oxford) 2010, 49:2420-2428.
20. Schiopu E., Hsu V.M., Impens A.J., et al. Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. J Rheumatol 2009, 36:2264-2268.